Rhythm Pharmaceuticals (NASDAQ:RYTM) Given New $131.00 Price Target at Citigroup

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price objective lowered by Citigroup from $136.00 to $131.00 in a research report issued on Tuesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s target price points to a potential upside of 45.83% from the company’s current price.

Several other equities research analysts have also commented on the company. Jefferies Financial Group restated a “buy” rating and issued a $125.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, March 3rd. Citizens Jmp reduced their price target on Rhythm Pharmaceuticals from $176.00 to $152.00 and set a “market outperform” rating for the company in a research report on Tuesday. Wells Fargo & Company raised their price objective on Rhythm Pharmaceuticals from $136.00 to $143.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Stifel Nicolaus set a $131.00 price objective on Rhythm Pharmaceuticals in a research note on Thursday, February 26th. Finally, The Goldman Sachs Group raised their target price on shares of Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Rhythm Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $131.75.

Rhythm Pharmaceuticals Stock Down 0.8%

Shares of Rhythm Pharmaceuticals stock traded down $0.68 during trading hours on Tuesday, reaching $89.83. 308,818 shares of the stock traded hands, compared to its average volume of 711,385. The company has a 50 day moving average price of $100.00 and a 200 day moving average price of $102.91. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of -28.86 and a beta of 2.06. Rhythm Pharmaceuticals has a one year low of $45.90 and a one year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.06. The firm had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. Rhythm Pharmaceuticals had a negative net margin of 103.57% and a negative return on equity of 266.56%. The business’s quarterly revenue was up 36.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.72) EPS. Sell-side analysts anticipate that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 5,614 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the sale, the chief accounting officer owned 160 shares in the company, valued at $14,329.60. The trade was a 97.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. The trade was a 3.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 27,267 shares of company stock valued at $2,719,955. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. increased its stake in Rhythm Pharmaceuticals by 17.3% in the 4th quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock worth $713,618,000 after acquiring an additional 985,478 shares during the last quarter. Vanguard Group Inc. increased its position in Rhythm Pharmaceuticals by 24.3% in the fourth quarter. Vanguard Group Inc. now owns 6,210,916 shares of the company’s stock worth $664,816,000 after purchasing an additional 1,214,489 shares during the last quarter. State Street Corp raised its stake in Rhythm Pharmaceuticals by 8.4% during the fourth quarter. State Street Corp now owns 2,198,615 shares of the company’s stock valued at $235,340,000 after purchasing an additional 169,964 shares in the last quarter. Federated Hermes Inc. raised its stake in Rhythm Pharmaceuticals by 2.5% during the third quarter. Federated Hermes Inc. now owns 1,727,885 shares of the company’s stock valued at $174,499,000 after purchasing an additional 41,391 shares in the last quarter. Finally, Westfield Capital Management Co. LP lifted its position in Rhythm Pharmaceuticals by 21.5% during the second quarter. Westfield Capital Management Co. LP now owns 1,629,468 shares of the company’s stock valued at $102,966,000 after purchasing an additional 288,376 shares during the last quarter.

Rhythm Pharmaceuticals News Roundup

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Company reported strong commercial momentum and an earnings beat: FY25 revenue grew ~50% to $194.8M driven by IMCIVREE (setmelanotide), and the Q4 results beat expectations — supporting upside ahead of the March 20 PDUFA for acquired hypothalamic obesity. FY25 revenue/PDUFA article
• Positive Sentiment: Major brokers cut price targets but kept positive ratings — signaling continued analyst conviction: Citizens Jmp to $152 (market outperform), BofA to $139 (buy), Morgan Stanley to $136 (overweight), Needham to $130 (buy); all still imply meaningful upside from current levels. Benzinga: analyst moves TickerReport: Needham note
• Neutral Sentiment: Company-hosted transcript and slide deck from the Phase 3 EMANATE topline presentation are available for review — useful for investors digging into subgroup and post‑hoc details. Seeking Alpha: transcript Seeking Alpha: slideshow
• Negative Sentiment: Topline EMANATE Phase 3: the program failed to meet pre‑specified primary endpoints in four substudies — a material clinical setback that is pressuring the stock and raising near‑term uncertainty around label expansion and commercial prospects. Reuters: trial fail
• Negative Sentiment: Company press release confirms four substudies did not meet endpoints, though post‑hoc analyses showed statistically significant BMI reductions in select heterozygous genotypes — this mixed readout keeps regulatory and commercial outcomes uncertain. GlobeNewswire: EMANATE topline

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.